Lilly is making a larger bet on depression treatment Eli Lilly is moving deeper into neuroscience with a deal to acquire AtaiBeckley, a clinical-stage biopharmaceutical company developing experimental therapies for treatment-resistant depression. AtaiBeckley stock jumped 30% in pre-market trading Thursday
Nvidia is turning general AI agents into specialized research assistants Nvidia is expanding its healthcare and life-sciences business with a new software platform designed to help AI agents perform complex scientific work. The BioNeMo Agent Toolkit connects general-purpose AI systems
A major funding round just validated one of biotech’s most-watched AI platforms Isomorphic Labs said it raised $2.1 billion in a new financing round, with Thrive Capital returning as lead investor and existing backers Alphabet and GV also participating, alongside
A stronger debut just added to biotech’s improving IPO tone Odyssey Therapeutics opened at $20, above its $18 IPO price, in a debut that gave the Boston-based biotech an initial public valuation just under $900 million. That followed an upsized
What Happened Eli Lilly said it will acquire biotech company Kelonia Therapeutics in a deal worth up to $7 billion, giving the drugmaker a bigger foothold in next-generation cell therapy and cancer treatment. Lilly said it will pay $3.25 billion
What Happened UnitedHealth Group (UNH) and other major health insurers rallied on Tuesday after the Centers for Medicare & Medicaid Services, or CMS, said it would increase payments for Medicare Advantage plans next year. The agency said payments to insurers
From Europe’s Most Valuable Company to Market Reality Novo Nordisk’s meteoric rise during the Wegovy era has officially come full circle. Shares of the Danish drugmaker plunged more than 16%, wiping out the remaining gains tied to the explosive growth
Novo Nordisk Pushes Back on $49 Wegovy Alternative Novo Nordisk said Thursday it will pursue legal and regulatory action against Hims & Hers after the telehealth firm announced plans to sell a low-cost copy of Novo’s blockbuster Wegovy weight loss
What Was Said And Why It Matters During a cabinet meeting at the White House, the U.S. President said he spoke with the head of Eli Lilly (LLY) and was told the company is building six plants in the United States. The comments point to continued momentum behind
UnitedHealth Profit Outlook Beats — But Medicare Shock Dominates Shares of UnitedHealth Group fell after the insurer delivered a slightly better-than-expected 2026 profit forecast, overshadowed by a sharply disappointing proposal for Medicare Advantage reimbursement rates. The reaction highlights how sensitive
Lilly is making a larger bet on depression treatment Eli Lilly is moving deeper into
Nvidia is turning general AI agents into specialized research assistants Nvidia is expanding its healthcare
A major funding round just validated one of biotech’s most-watched AI platforms Isomorphic Labs said
A stronger debut just added to biotech’s improving IPO tone Odyssey Therapeutics opened at $20,
What Happened Eli Lilly said it will acquire biotech company Kelonia Therapeutics in a deal
What Happened UnitedHealth Group (UNH) and other major health insurers rallied on Tuesday after the
From Europe’s Most Valuable Company to Market Reality Novo Nordisk’s meteoric rise during the Wegovy
Novo Nordisk Pushes Back on $49 Wegovy Alternative Novo Nordisk said Thursday it will pursue
What Was Said And Why It Matters During a cabinet meeting at the White House, the U.S.
UnitedHealth Profit Outlook Beats — But Medicare Shock Dominates Shares of UnitedHealth Group fell after
